Lipocine Inc LPCN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LPCN is a good fit for your portfolio.
News
-
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
-
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
-
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
-
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
-
Lipocine to Present at 36th Annual Roth Conference
-
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
-
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
Trading Information
- Previous Close Price
- $4.80
- Day Range
- $4.51–5.01
- 52-Week Range
- $2.32–7.06
- Bid/Ask
- $4.49 / $5.00
- Market Cap
- $24.08 Mil
- Volume/Avg
- 1,123 / 68,708
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.lipocine.com
Valuation
|
Metric
|
LPCN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.33 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
LPCN
Financial Strength
|
Metric
|
LPCN
|
|---|---|
Quick Ratio | 8.39 |
Current Ratio | 8.69 |
Interest Coverage | — |
Quick Ratio
LPCN
Profitability
|
Metric
|
LPCN
|
|---|---|
Return on Assets (Normalized) | −45.61% |
Return on Equity (Normalized) | −49.15% |
Return on Invested Capital (Normalized) | −52.95% |
Return on Assets
LPCN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sxkkdsns | Lzm | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tpchwdgdb | Vvcmg | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bcgtrhz | Bjkfwnr | $99.6 Bil | |
MRNA
| Moderna Inc | Lfymqdpwl | Gjr | $38.8 Bil | |
ARGX
| argenx SE ADR | Mqyxfyspm | Hcry | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Qyypsmlx | Tbmm | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xdspwzwt | Zncrfgl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pdqqclt | Lmnfpn | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Npmvghjrf | Gylwmq | $12.4 Bil | |
INCY
| Incyte Corp | Bbxzzlfl | Rdtpcm | $11.9 Bil |